Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
9vc is a venture capital organization established to create, augment, and invest in companies focused on late-stage drug development programs. Founded with the mission to facilitate the reincarnation of drugs to patients, 9vc aims to provide substantial value to investors. The firm employs a proprietary search engine that enables it to identify and build tech-bio partnerships, enhancing its investment strategy.
Currently, 9vc focuses on late-stage investments, particularly in Series C and growth equity rounds. The firm has a notable portfolio company, Leona Bio (NASDAQ: LONA), which is advancing a phase 2 ready pipeline in drug development. 9vc's expertise in the biotech and healthcare sectors positions it as a significant player in the investment landscape.
9vc invests primarily in late-stage clinical development companies, particularly those involved in drug development within the biotech and healthcare sectors. The organization emphasizes asset arbitrage, seeking to capture value in opportunities that others may overlook. Their investment strategy combines technology and expertise to reduce risk and accelerate the realization of value.
Investment checks typically occur in Series C and growth equity stages, allowing 9vc to support companies that are nearing commercialization. The firm’s proprietary search engine plays a crucial role in identifying promising investment opportunities and building strategic partnerships in the tech-bio space.
9vc's portfolio includes:
Anat Naschitz: Investor, Company and Fund Creator with a focus on biotech investments.
Jan Schultink: Tech Entrepreneur and Builder with experience in scaling biotech companies.
Jeremy Levin: Advisory Board Chairman and CEO of OvidRx, bringing extensive leadership experience in the biotech sector.
Paul Sekhri: Advisory Board CEO of vTv, with a strong background in healthcare management.
Danny Bar-Zohar: Advisory Board CEO of Merck KGaA Healthcare, contributing deep industry knowledge.
Johan Luthman: Advisory Board R&D Leader with expertise in drug development.
Aaron Gershenberg: Advisory Board CEO of Blue Chip Funds of Funds, specializing in investment strategies.
Paul Biondi: Advisory Board General Partner and President of Flagship Pioneering Medicines, with a focus on innovative drug development.
To pitch to 9vc, founders should visit 9vc.co and submit their proposals through the provided channels. It is advisable to include comprehensive details about the startup's drug development strategy and market positioning.
As of October 2023, 9vc continues to focus on late-stage investments in the biotech sector, particularly through their portfolio company, Leona Bio (NASDAQ: LONA), which is advancing its drug development pipeline.
There have been no recent public announcements regarding new fund raises or additional portfolio companies.
What are 9vc's investment criteria?
9vc focuses on late-stage clinical development companies, particularly in the biotech and healthcare sectors. They emphasize asset arbitrage and seek to invest in opportunities that may be overlooked by others.
How can I pitch to 9vc?
Founders can submit their pitches through the official website at 9vc.co. It is recommended to include detailed information about the company's drug development programs and market potential.
What makes 9vc different from other venture capital firms?
9vc utilizes a proprietary search engine to identify investment opportunities and build tech-bio partnerships, which enhances their ability to reduce risk and accelerate value realization in drug development.
What is the geographic scope of 9vc's investments?
While specific geographic preferences are not detailed, 9vc's focus on biotech and healthcare suggests a broad interest in markets where these sectors are thriving.
What is the typical check size for investments?
9vc primarily invests in Series C and growth equity rounds, which typically involve larger check sizes, although specific amounts are not disclosed.
What kind of post-investment involvement does 9vc have?
9vc's team, which includes experienced professionals from the biotech industry, likely provides operational support and strategic guidance to portfolio companies, although specific details are not provided.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.